Kevin DeGeeter
Stock Analyst at Oppenheimer
(1.70)
# 1,432
Out of 4,641 analysts
44
Total ratings
31.43%
Success rate
44.36%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.08 | +1,937.04% | 1 | Apr 19, 2022 | |
| ORIC ORIC Pharmaceuticals | Downgrades: Perform | n/a | $8.82 | - | 1 | Mar 22, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $4.69 | +411.73% | 4 | Feb 25, 2022 | |
| NVCR NovoCure | Upgrades: Outperform | $98 | $16.18 | +505.69% | 3 | Feb 2, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $19.18 | +551.72% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $2.00 | +800.00% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $7.05 | +169.50% | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $1.26 | - | 1 | Oct 1, 2021 | |
| PRTG Portage Biotech | Initiates: Outperform | $600 | $5.64 | +10,538.30% | 1 | Sep 21, 2021 | |
| PANW Palo Alto Networks | Maintains: Outperform | $150 → $158 | $358.19 | -55.80% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $70.27 | +120.58% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.56 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $5.36 | +366.42% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $255 | $1.06 | +23,956.60% | 1 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $180 | $2.67 | +6,641.57% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $42.28 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.97 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $17.59 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.04 | +2,350.98% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $0.29 | +4,988.20% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $10.00 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $150 | $0.67 | +22,361.81% | 1 | Aug 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $11.30 | +1,891.15% | 1 | Apr 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $22.32 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $3.06 | - | 2 | Jan 4, 2017 |
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.08
Upside: +1,937.04%
ORIC Pharmaceuticals
Mar 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $8.82
Upside: -
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $4.69
Upside: +411.73%
NovoCure
Feb 2, 2022
Upgrades: Outperform
Price Target: $98
Current: $16.18
Upside: +505.69%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $19.18
Upside: +551.72%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $2.00
Upside: +800.00%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $7.05
Upside: +169.50%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $1.26
Upside: -
Portage Biotech
Sep 21, 2021
Initiates: Outperform
Price Target: $600
Current: $5.64
Upside: +10,538.30%
Palo Alto Networks
Aug 24, 2021
Maintains: Outperform
Price Target: $150 → $158
Current: $358.19
Upside: -55.80%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $70.27
Upside: +120.58%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $0.56
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $5.36
Upside: +366.42%
Apr 30, 2021
Initiates: Outperform
Price Target: $255
Current: $1.06
Upside: +23,956.60%
Mar 2, 2021
Initiates: Outperform
Price Target: $180
Current: $2.67
Upside: +6,641.57%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $42.28
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.97
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $17.59
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $50
Current: $2.04
Upside: +2,350.98%
Apr 8, 2020
Initiates: Outperform
Price Target: $15
Current: $0.29
Upside: +4,988.20%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $10.00
Upside: -
Aug 3, 2017
Initiates: Buy
Price Target: $150
Current: $0.67
Upside: +22,361.81%
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $11.30
Upside: +1,891.15%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $22.32
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $3.06
Upside: -